Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y ibritumomab tiuxetan (Zevalin) in patients with extra-nodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)
2007-004289-42Phase 2Terminated
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Sep 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in marginal zone B-cell lymphoma (MZL), sponsored by National and Kapodistrian University of Athens. Primary endpoint: Overall response rate at 3 months. Started Sep 2007; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2007-004289-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004289-42.